2026年政府资助法案重启FDA罕见儿科疾病凭证计划
FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
生物技术与制药领域的最新动态
FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
UK consortium to use 10x Genomics platform for AI-driven cancer research - Investing.com Canada
FTC settles insulin lawsuit with Express Scripts
AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness - simplywall.st
Rare pediatric PRV program reauthorized until 2029 via government funding law
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
Financings for Feb. 4, 2026
In the clinic for Feb. 4, 2026
Other news to note for Feb. 4, 2026
Regulatory actions for Feb. 4, 2026
BARDA offers $100M in prize money for antiviral development
PharosAI and 10x Genomics partner to transform cancer research with AI and spatial biology - marketscreener.com
Novo shares tumble by double digits on grim sales outlook
Lilly soars again as fast-selling weight loss drugs top Wall Street projections
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA demands better response from Abbott over Libre inspection violations